Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Inhaler Stories

2011-12-21 06:25:30

(Ivanhoe Newswire) — Adding inhaled powder mannitol to standard therapy for cystic fibrosis produced consistent lung function improvement for up to 52 weeks, according to this study. Mannitol treatment is not only efficient and safe, but it´s easy to administer as well. In the double-blind study, which was supported by Pharmaxis Limited, 318 patients were randomized to treatment with 400 mg bid inhaled mannitol or 50 mg bid inhaled mannitol (control group) for 26 weeks, followed...

2011-12-19 04:55:00

DUSSELDORF, Germany, December 19, 2011 /PRNewswire/ -- - Growth in demand for pharmaceutical and medical plastic systems - Gerresheimer invests around EUR 25 million in its Pfreimd plant - 130 new jobs Gerresheimer AG, one of the world's leading suppliers to the pharma and healthcare industry, further invests in the growth market of complex plastic systems for pharmaceutical and medical applications. Production capacity is being...

2011-12-16 12:57:31

Adding inhaled dry powder mannitol to standard therapy for cystic fibrosis produced sustained improvement in lung function for up to 52 weeks, according to a new study. Along with the treatment's efficacy and good safety profile, the convenience and ease of administration of mannitol treatment may improve adherence with therapy in these patients. In the double-blind study, which was supported by Pharmaxis Limited, 318 patients were randomized to treatment with 400 mg bid inhaled mannitol...

2011-12-07 08:00:00

REDWOOD CITY, Calif., Dec. 7, 2011 /PRNewswire/ -- Pearl Therapeutics Inc. today announced positive top-line results from a randomized, double-blind, Phase 2b, dose-ranging study of glycopyrrolate, a long-acting muscarinic agonist (LAMA) delivered twice a day (BID) via metered-dose inhaler (GP MDI; PT001) in patients with moderate-to-severe COPD. Four doses of GP MDI were compared to placebo and Atrovent® HFA Inhalation Aerosol, a short-acting muscarinic...

2011-11-09 06:30:00

PITTSBURGH, Nov. 9, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has entered into an agreement with Pfizer for the exclusive worldwide rights to develop, manufacture and commercialize Pfizer's generic equivalent to GlaxoSmithKline's Advair® Diskus and Seretide® Diskus incorporating Pfizer's proprietary dry powder inhaler delivery platform. Advair® Diskus and Seretide® Diskus are inhaled...

2011-10-28 13:58:00

Groups Say Congress Should Issue Vouchers to Assist with Transition from Epinephrine Inhalers, Monitor Patient Safety WASHINGTON, Oct. 28, 2011 /PRNewswire-USNewswire/ -- New legislation from U.S. Senator Pat Roberts (R-KS) and an amendment by Senator Jim DeMint (R-SC) seek to allow epinephrine inhalers that contain chlorofluorocarbon (CFC) propellants to stay on the market, rather than being removed as agreed to in an international treaty ratified by all U.N.-recognized nations. Allergy...

2011-10-28 13:00:00

REDWOOD CITY, Calif., Oct. 28, 2011 /PRNewswire/ -- Pearl Therapeutics Inc. presented data elucidating the robust aerosol performance and physicochemical foundations of the Company's cosuspension technology which uses spray-dried, low-density porous particles to deliver drug microcrystals via pressurized metered dose inhalers (MDIs). Two posters were presented this week at the 25th American Association of Pharmaceutical Scientists annual meeting in Washington DC. "These results...

2011-10-19 12:21:00

LOURES, Portugal, October 19, 2011 /PRNewswire/ -- Hovione today announced the launch of its Rapid Proof of Concept Study for the development of dry powder inhalation (DPI) products. Building on Hovione's well established DPI development capability, the new service simplifies the development of formulations, producing a proof of concept formulation of a client's molecule in just a few weeks. Hovione has simplified DPI product development, reduced complexity and...

2011-10-07 20:18:00

RIDGEFIELD, Conn., Oct. 7, 2011 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved COMBIVENT RESPIMAT, a new, propellant-free inhaler product that uses a slow-moving mist to deliver the same active ingredients of COMBIVENT Inhalation Aerosol in a metered dose inhaler (COMBIVENT MDI). COMBIVENT RESPIMAT will be available for patients in mid-2012. COMBIVENT RESPIMAT and COMBIVENT MDI are indicated for use...

2011-10-06 05:00:00

MOUNTAIN VIEW, Calif. and BARCELONA, Spain, Oct. 6, 2011 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) and Grupo Ferrer International, S.A., announced today that they entered into a commercial partnership for Adasuve(TM) (Staccato® loxapine). ADASUVE is Alexza's lead program, based on the company's proprietary technology, the Staccato system. Grupo Ferrer is a leading pharmaceutical company in Europe with extensive operations in the Americas, and will be...